Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Longboard Pharmaceuticals (LBPH)
NASDAQ:LBPH
RESEARCH TOOLSreports
Holding LBPH?
Track your performance easily
LBPH Stock Chart & Stats
Day’s Range$59.98 - $60.03
52-Week Range― - ―
Previous Close$59.96
Volume655.80K
Average Volume (3M)N/A
Market Cap
$2.34B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding39,045,703
10 Day Avg. Volume751,775
30 Day Avg. Volume954,567
Standard Deviation0.47
R-Squared0.01
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)8.51
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-28.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$64.00Price Target Upside6.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Longboard Pharmaceuticals News
PremiumCompany Announcements
Longboard Pharmaceuticals Completes Acquisition and Delisting
PremiumCompany Announcements
Longboard Pharmaceuticals Advances Neurological Treatments
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyThe acquisition by Lundbeck is viewed as an ideal outcome for all parties involved.
Drug DevelopmentBexicaserin is positioned for success in epilepsy with blockbuster potential, supported by an expanded Phase 3 program.
Financial PerformanceThe acquisition price of $60 per share represents a 77% premium to LBPH's 30-day volume-weighted average price.
Bears Say
Investor ConcernsInvestor concerns may have driven the deal to consummate earlier than expected, due to a lack of material value-creating catalysts for Longboard Pharmaceuticals over the next 12-18 months.
Revenue EstimatesUpdated revenue estimates reflect Lundbeck's guidance, which calls for estimated global peak sales between $1.5B-$2.0B, lower than the prior estimate of $2.6B.
Stock RatingThe stock rating for Longboard Pharmaceuticals has been downgraded to Neutral.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LBPH FAQ
What was Longboard Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Longboard Pharmaceuticals’s market cap?
Currently, no data Available
When is Longboard Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Longboard Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Longboard Pharmaceuticals overvalued?
According to Wall Street analysts Longboard Pharmaceuticals’s price is currently Undervalued.
Does Longboard Pharmaceuticals pay dividends?
Longboard Pharmaceuticals does not currently pay dividends.
What is Longboard Pharmaceuticals’s EPS estimate?
Longboard Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Longboard Pharmaceuticals have?
Currently, no data Available
What happened to Longboard Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Longboard Pharmaceuticals?
Among the largest hedge funds holding Longboard Pharmaceuticals’s share is Farallon Capital Management, L.L.C.. It holds Longboard Pharmaceuticals’s shares valued at 105M.
---
Longboard Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$64.00 (6.70% Upside)
$64.00 (6.70% Upside)
Blogger Sentiment
Neutral
LBPH Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.3%
Last 30 Days ▼ 13.8%
Last 30 Days ▼ 13.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1162.73%
12-Months-Change
Fundamentals
Return on Equity
-46.66%
Trailing 12-Months
Asset Growth
404.56%
Trailing 12-Months
Company Description
Longboard Pharmaceuticals
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its pipeline includes LP352, LP143, and LP659.
---
LBPH Stock 12 Month Forecast
Average Price Target
$64.00
▲(6.70% Upside)
Technical Analysis
Aquestive Therapeutics
―
Pliant Therapeutics
―
Bioxcel Therapeutics
―
Kiniksa Pharmaceuticals
―
Best Analysts Covering LBPH
1 Year
1 Year Success Rate
21/21 ratings generated profit
1 Year Average Return
+203.62%
reiterated a buy rating 2 months ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +203.62% per trade.
---